Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative ferric carboxymaltose to reduce postoperative blood transfusion in bilateral total knee arthroplasty
KCT0004015Phase 4Not yet recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferric carboxymaltose in knee osteoarthritis (OA), sponsored by JW Pharmaceutical Corporation. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on KCT0004015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004015.